Immune Tolerance Network   A clinical research consortium sponsored by NIAID and JDRF
START logoA clinical research study of thymoglobulin to arrest type 1 diabetes


 

Participating in the START trial

Qualified individuals who are interested in participating in the START trial will be asked to attend a screening appointment to further assess whether you are a good fit for this trial. If the screening process indicates that you are eligible and you decide to participate, you will be enrolled as a volunteer in the trial.

At the beginning of the trial, you (or your child) will stay in the hospital for 5-8 days to receive the study treatment (or placebo).

All participants in the START trial will receive, at no cost to themselves:

  • participation in an intensive diabetes management program
  • access to study doctors or nurses to discuss questions and concerns
  • regular counselling with diabetes educators
  • regular physical exams
  • regular laboratory testing to assess diabetes progression
  • a complimentary blood glucose monitor and supplies for the duration of the study

Some compensation is also available: START staff will provide more details at your request.

Participants will also be asked to attend several appointments over a period of 2 years.

Who can Participate?

To be eligible to for the START trial, you or your child must be between the ages of 12-35 years old and diagnosed with type 1 diabetes within the last 3 months. To be eligible to participate in the START trial, you must:

  • be aged 12-35
  • have been diagnosed with type 1 diabetes within the past 3 months

If you believe you may be eligible to participate, contact a clinical site nearest you for more information.

Recruitment is now closed.

For information on additional ITN trials for people recently diagnosed with type 1 diabetes, please visit:

Retain Study
www.retainstudy.org

T1DAL Study
www.t1dal.org

spacer

Downloads

START Brochure (871 kb)

FAQ (438 kb)

Physician Reference Card (154 kb)

Do you have questions? Contact us or read the FAQ.

spacer
spacer
 
Terms of Use | Privacy | Accessibility
©2007, Immune Tolerance Network
spacer